Figure 2.

Percentage of infliximab- and placebo-treated patients demonstrating ACR20, ACR50, and ACR70 responses at 16 weeks. ACR, American College of Rheumatology. P < 0.0001. Reproduced with permission from [32].

Gottlieb and Antoni Arthritis Res Ther 2004 6(Suppl 2):S31-S35   doi:10.1186/ar1016